{"id":1409,"date":"2024-02-22T18:48:25","date_gmt":"2024-02-22T18:48:25","guid":{"rendered":"https:\/\/stoxpo.com\/?p=1409"},"modified":"2024-02-22T18:48:25","modified_gmt":"2024-02-22T18:48:25","slug":"moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/","title":{"rendered":"Moderna Reports Strong Spikevax Sales and Expands Vaccine Portfolio"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Moderna Inc (MRNA) witnessed a surge in its stock following its fourth-quarter 2023 financial report, which showcased robust revenues of $2.81 billion from its Spikevax (COVID-19 vaccine), surpassing consensus estimates. Despite a 43% year-on-year decline in net product sales, primarily due to lower sales volume, the company achieved $6.7 billion in vaccine sales for fiscal 2023, in line with its financial framework.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In addition to its strong performance in the U.S. retail segment, Moderna reported fourth-quarter earnings per share (EPS) of $0.55, exceeding analyst predictions. The company also outlined plans for its RSV vaccine (mRNA-1345), expecting initial regulatory approvals in the first half of 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Looking ahead, Moderna reaffirmed its fiscal year 2024 product sales outlook and announced its expansion into key international markets, with plans to launch its RSV vaccine in Australia and Germany in 2024. Moreover, the company anticipates significant revenue from its respiratory franchise in 2024, alongside continued investment in research and development to drive innovation. As a result, MRNA shares rose by 7.57% to $94.22, reflecting investor confidence in the company&#8217;s growth prospects.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Moderna Inc (MRNA) witnessed a surge in its stock following its fourth-quarter 2023 financial report, which showcased robust revenues of $2.81 billion from its Spikevax (COVID-19 vaccine), surpassing consensus estimates. Despite a 43% year-on-year decline in net product sales, primarily due to lower sales volume, the company achieved $6.7 billion in vaccine sales for fiscal [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1412,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[308,361],"tags":[],"coauthors":[453],"class_list":["post-1409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-large-cap"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Moderna Reports Strong Spikevax Sales and Expands Vaccine Portfolio - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moderna Reports Strong Spikevax Sales and Expands Vaccine Portfolio - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Moderna Inc (MRNA) witnessed a surge in its stock following its fourth-quarter 2023 financial report, which showcased robust revenues of $2.81 billion from its Spikevax (COVID-19 vaccine), surpassing consensus estimates. Despite a 43% year-on-year decline in net product sales, primarily due to lower sales volume, the company achieved $6.7 billion in vaccine sales for fiscal [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-22T18:48:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-mufid-majnun-9240711-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Liliana Vida\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Liliana Vida\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\\\/\"},\"author\":{\"name\":\"Liliana Vida\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\"},\"headline\":\"Moderna Reports Strong Spikevax Sales and Expands Vaccine Portfolio\",\"datePublished\":\"2024-02-22T18:48:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\\\/\"},\"wordCount\":176,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-mufid-majnun-9240711-scaled.jpg\",\"articleSection\":[\"Biotechnology\",\"Large-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\\\/\",\"name\":\"Moderna Reports Strong Spikevax Sales and Expands Vaccine Portfolio - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-mufid-majnun-9240711-scaled.jpg\",\"datePublished\":\"2024-02-22T18:48:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-mufid-majnun-9240711-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-mufid-majnun-9240711-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"moderna-vaccine-2\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moderna Reports Strong Spikevax Sales and Expands Vaccine Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\",\"name\":\"Liliana Vida\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"caption\":\"Liliana Vida\"},\"description\":\"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/stoxpo-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moderna Reports Strong Spikevax Sales and Expands Vaccine Portfolio - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"Moderna Reports Strong Spikevax Sales and Expands Vaccine Portfolio - Stoxpo","og_description":"Moderna Inc (MRNA) witnessed a surge in its stock following its fourth-quarter 2023 financial report, which showcased robust revenues of $2.81 billion from its Spikevax (COVID-19 vaccine), surpassing consensus estimates. Despite a 43% year-on-year decline in net product sales, primarily due to lower sales volume, the company achieved $6.7 billion in vaccine sales for fiscal [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/","og_site_name":"Stoxpo","article_published_time":"2024-02-22T18:48:25+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-mufid-majnun-9240711-scaled.jpg","type":"image\/jpeg"}],"author":"Liliana Vida","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Liliana Vida","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/"},"author":{"name":"Liliana Vida","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1"},"headline":"Moderna Reports Strong Spikevax Sales and Expands Vaccine Portfolio","datePublished":"2024-02-22T18:48:25+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/"},"wordCount":176,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-mufid-majnun-9240711-scaled.jpg","articleSection":["Biotechnology","Large-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/","url":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/","name":"Moderna Reports Strong Spikevax Sales and Expands Vaccine Portfolio - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-mufid-majnun-9240711-scaled.jpg","datePublished":"2024-02-22T18:48:25+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-mufid-majnun-9240711-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-mufid-majnun-9240711-scaled.jpg","width":2560,"height":1707,"caption":"moderna-vaccine-2"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/moderna-reports-strong-spikevax-sales-and-expands-vaccine-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Moderna Reports Strong Spikevax Sales and Expands Vaccine Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1","name":"Liliana Vida","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6","url":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","caption":"Liliana Vida"},"description":"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/stoxpo-com\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=1409"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1409\/revisions"}],"predecessor-version":[{"id":1414,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1409\/revisions\/1414"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1412"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=1409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=1409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=1409"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=1409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}